Breaking

Trading Delayed in Newest Addition to Tel Aviv Flagship Indices

At the company’s request, trading in biomedical company Alpha Tau will open today on the Tel Aviv Stock Exchange (TASE) alongside Nasdaq • An hour before the opening, the company will present investors with interim results from a brain cancer trial • Last month, the FDA approved the trial’s expansion

Photo: Shutterstock

Only this month, Alpha Tau Medical joined the TA-90 and TA-125 indices, and today (Monday) the company asked to delay the opening of trading in its shares on the Tel Aviv Stock Exchange (TASE) until 16:30, when trading opens on Nasdaq. This follows the release of a material immediate report. Alpha Tau yesterday published interim results from a trial in recurrent glioblastoma and will hold an investor call today at 15:30 Israel time to present the findings.

Medicine, illustration
Medicine, illustration | Photo: Shutterstock

The company will hold an investor call today at 15:30 Israel time, an hour before trading in the stock opens. During the call, company management and Dr. Joshua Palmer of The Ohio State University, the lead investigator in the REGAIN trial it conducted on brain cancer patients, will present the interim results unveiled at a neuro-oncology conference in Philadelphia.

Alpha Tau was founded in 2016 and began trading on Nasdaq in 2022 after merging with a SPAC. In August this year, it also began trading in Tel Aviv, without raising capital as part of the listing. The company’s CEO, Uzi Sofer, said at the time that interest among Israeli investors had increased and that some had asked to invest in shekels or through the local indices. In the TASE’s latest index update earlier this month, Alpha Tau entered the TA-90 and TA-125 and became one of three biomedical companies in the TA-125.

Alph

U.S. Food and Drug Administration (FDA)
U.S. Food and Drug Administration (FDA) | Photo: Shutterstock

The company is developing a treatment based on inserting tiny sources of alpha radiation directly into the tumor. The technology, developed at Tel Aviv University, is designed to concentrate the radiation in the tumor and reduce exposure to the surrounding healthy tissue. The REGAIN trial was conducted in the U.S. among patients with glioblastoma, a malignant brain tumor that had recurred after previous radiation treatment and could not be surgically removed. According to an update presented by the company at a neuro-oncology conference in Philadelphia, all eight patients treated in the trial were alive as of November 11, while six had already reached the MRI response assessment stage. Five of them had no measurable tumor remaining at the treated site, a finding classified as a complete response. Last month, the company received FDA approval to expand the treatment trial to 20 patients.

The trial results could also affect Oramed Pharmaceuticals, the biotechnology company that holds about 17% of Alpha Tau. Oramed invested about $38.2 million in purchasing the shares, and at the end of September, the carrying value of the investment, including warrants, was about $252 million. In the first nine months of the year, Oramed recorded revaluation gains of about $174.5 million on the investment.

Key takeaways

  • Alpha Tau Medical asked to delay trading in its Tel Aviv Stock Exchange shares until 16:30, when Nasdaq trading opens, after publishing a material immediate report.
  • The company released interim results from the REGAIN trial in recurrent glioblastoma and will hold an investor call at 15:30 Israel time to present the findings.
  • Alpha Tau entered the TA-90 and TA-125 earlier this month and is now one of three biomedical companies in the TA-125.
  • Last month, the company received FDA approval to expand the treatment trial to 20 patients.
  • Oramed Pharmaceuticals, which holds about 17% of Alpha Tau, could be affected by the trial results; it recorded revaluation gains of about $174.5 million in the first nine months of the year.

Questions and answers

Why was trading in Alpha Tau delayed on TASE?
At the company’s request, trading in Alpha Tau shares on TASE was delayed until 16:30, the time Nasdaq opens. The delay followed the publication of a material immediate report and the release of interim trial results.
What did Alpha Tau present from the REGAIN trial?
Alpha Tau published interim results from a trial in recurrent glioblastoma and said it would discuss them in an investor call at 15:30 Israel time. The company said all eight patients treated were alive as of November 11, and five had no measurable tumor remaining at the treated site.
What is Alpha Tau developing?
Alpha Tau is developing a treatment based on inserting tiny sources of alpha radiation directly into the tumor. The technology, developed at Tel Aviv University, is designed to concentrate radiation in the tumor and reduce exposure to surrounding healthy tissue.

Share this story

About the writer

Sharon Birkman

Writes for TV10, Israel’s economic channel. This story was translated from the original Hebrew.

More stories by Sharon Birkman

More for you